
[006a] In one aspect of the present disclosure, there is provided a compound, or pharmaceutically acceptable salt thereof, of Formula **I**:



I

wherein:

R^1 is selected from the group consisting of H and halide;

R^2 is 6-10-membered heteroaryl(R^4);

R^3 is selected from the group consisting of H, unsubstituted -C_{1-9} alkyl, -(C_{1-6} alkyl)N(R^{68})$_2$, -(C_{2-6} alkyl)O(C_{1-6} alkyl), -spirocyclic heterocyclyl(R^8)$_p$, and -(C_{1-3} alkyl)heterocyclyl(R^9)$_p$

R^4 is 1 substituent attached to the 6-10-membered heteroaryl and is selected from the group consisting of unsubstituted -C_{1-6} haloalkyl, -heterocyclyl(R^{22})$_p$, -NHC(=O)R^{24}, and -(C_{1-6} alkyl)$_n$N(R^{25})$_2$;

each R^7 is a substituent attached to the carbocyclyl ring and is independently selected at each occurrence from the group consisting of H, halide, and -N(R^{25})$_2$;

each R^8 is a substituent attached to the heterocyclyl ring and is independently selected at each occurrence from the group consisting of H, halide, -(C_{1-3} alkyl)carbocyclyl(R^7)$_p$, -(C_{1-3} alkyl)$_n$aryl(R^{11})$_q$, unsubstituted –C_{1-6} haloalkyl, and unsubstituted –C_{1-6} alkyl;

each R^9 is a substituent attached to the heterocyclyl ring and is independently selected at each occurrence from the group consisting of H and halide;

each R^{11} is a substituent attached to the aryl ring and is independently selected at each occurrence from the group consisting of H, halide, –C_{1-6} haloalkyl, and -C_{1-6} alkyl;

each R^{22} is a substituent attached to the heterocyclyl ring and is independently selected at each occurrence from the group consisting of H, halide, $-CF_3$, $-N(R^{25})_2$, and $-C_{1-6}$ alkyl;

each R^{24} is $-C_{1-6}$ alkyl;

each R^{25} is independently selected at each occurrence from the group consisting of H and $-C_{1-6}$ alkyl, alternatively, two adjacent R^{25} are taken together with the nitrogen atom to which they are attached to form a 3 to 7 membered heterocyclic ring;

each R^{30} is independently selected at each occurrence from the group consisting of H and $-C_{1-6}$ alkyl;

each R^{68} is independently selected at each occurrence from the group consisting of H and unsubstituted $-C_{1-6}$ alkyl;

each n is independently an integer of 0 to 1;

each p is independently an integer of 1 to 10;

each q is independently an integer of 1 to 5; and

wherein each alkyl, as used herein alone or as part of another group, refers to a branched, or straight chain chemical group containing only carbon and hydrogen, preferably comprising 1 to 9 carbon atoms, even more preferably methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl and neo-pentyl, wherein the alkyl groups are either unsubstituted or substituted with one or more substituents, or are saturated or unsaturated, at one or several positions.

[006b] In a further aspect of the present disclosure, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.


[006c] In another aspect of the present disclosure, there is provided a use of a compound as described herein, or a pharmaceutically acceptable salt thereof, in the preparation of a pharmaceutical composition for treating a disorder or disease in a patient, wherein the disorder or disease is selected from the group consisting of: cancer, pulmonary fibrosis, a bone or cartilage disease, a neurological disorder, osteoarthritis, lung disease, a fibrotic disorder.

[006d] In yet another aspect of the present disclosure, there is provided a use of a compound as described herein, or a pharmaceutically acceptable salt thereof, in the preparation of a pharmaceutical composition for treating a disorder or disease in a patient, wherein the disorder or disease is selected from the group consisting of: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.

[006e] In a further aspect of the present disclosure, there is provided a use of a compound as described herein, or a pharmaceutically acceptable salt thereof, in the preparation of a pharmaceutical composition for preventing or reducing angiogenesis in a patient.

WHAT IS CLAIMED IS:

1. A compound, or pharmaceutically acceptable salt thereof, of Formula **I**:



I

wherein:

R^1 is selected from the group consisting of H and halide;

R^2 is 6-10-membered heteroaryl(R^4);

R^3 is selected from the group consisting of H, unsubstituted -C_{1-9} alkyl, -(C_{1-6} alkyl)N(R^{68})$_2$, -(C_{2-6} alkyl)O(C_{1-6} alkyl), -spirocyclic heterocyclyl(R^8)$_p$, and -(C_{1-3} alkyl)heterocyclyl(R^9)$_p$;

R^4 is 1 substituent attached to the 6-10-membered heteroaryl and is selected from the group consisting of unsubstituted -C_{1-6} haloalkyl, -heterocyclyl(R^{22})$_p$, -NHC(=O)R^{24}, and -(C_{1-6} alkyl)$_n$N(R^{25})$_2$;

each R^7 is a substituent attached to the carbocyclyl ring and is independently selected at each occurrence from the group consisting of H, halide, and -N(R^{25})$_2$;

each R^8 is a substituent attached to the heterocyclyl ring and is independently selected at each occurrence from the group consisting of H, halide, -(C_{1-3} alkyl)carbocyclyl(R^7)$_p$, -(C_{1-3} alkyl)$_n$aryl(R^{11})$_q$, unsubstituted –C_{1-6} haloalkyl, and unsubstituted –C_{1-6} alkyl;

each R^9 is a substituent attached to the heterocyclyl ring and is independently selected at each occurrence from the group consisting of H and halide;

each R^{11} is a substituent attached to the aryl ring and is independently selected at each occurrence from the group consisting of H, halide, –C_{1-6} haloalkyl, and -C_{1-6} alkyl;

each R^{22} is a substituent attached to the heterocyclyl ring and is independently selected at each occurrence from the group consisting of H, halide, -CF_3, -N(R^{25})$_2$, and -C_{1-6} alkyl;

each R^{24} is -C_{1-6} alkyl;

each R^{25} is independently selected at each occurrence from the group consisting of H and -C_{1-6} alkyl, alternatively, two adjacent R^{25} are taken together with the nitrogen atom to which they are attached to form a 3 to 7 membered heterocyclic ring;

each R^{30} is independently selected at each occurrence from the group consisting of H and -C_{1-6} alkyl;

each R^{68} is independently selected at each occurrence from the group consisting of H and unsubstituted -C_{1-6} alkyl;

each n is independently an integer of 0 to 1;

each p is independently an integer of 1 to 10;

each q is independently an integer of 1 to 5; and

wherein each alkyl, as used herein alone or as part of another group, refers to a branched, or straight chain chemical group containing only carbon and hydrogen, preferably comprising 1 to 9 carbon atoms, even more preferably methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl and neo-pentyl, wherein the alkyl groups are either unsubstituted or substituted with one or more substituents, or are saturated or unsaturated, at one or several positions.

2. The compound of claim 1, wherein R^1 is selected from the group consisting of H, F, and Me.


3. The compound according to any one of claims 1-2, wherein R^1 is H.

4. The compound according to any one of claims 1-2, wherein R^1 is F.

5. The compound according to any one of claims 1-4, wherein R^2 is pyridinyl(R^4).

6. The compound according to any one of claims 1-5, wherein R^2 is pyridin-3-yl(R^4).


7. The compound according to any one of claims 1-6, wherein R^4 is -heterocyclyl(R^{22})$_p$.

8. The compound according to any one of claims 1-7, wherein R^4 is selected from the group consisting of 

.

9. The compound according to any one of claims 1-8, wherein R^3 is H.

10. The compound according to any one of claims 1-8, wherein R^3 is -C_{1-9} alkyl.

11. The compound according to any one of claims 1-8 and 10, wherein R^3 is selected from the group consisting of .

12. The compound of claim 1, wherein the compound of Formula **I** is selected from the group consisting of:

5-(5-aminopyridin-3-yl)-1H-indazole-3-carboxamide [**105**];

5-(5-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide [**106**];

5-(5-(piperidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide [**107**];

5-(5-morpholinopyridin-3-yl)-1H-indazole-3-carboxamide [**108**];

5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-indazole-3-carboxamide [**109**];

5-(5-(3,3-dimethylureido)pyridin-3-yl)-1H-indazole-3-carboxamide [**118**];

5-(5-(cyclopropanecarboxamido)pyridin-3-yl)-1H-indazole-3-carboxamide [**119**];

5-(5-aminopyridin-3-yl)-N-isopropyl-1H-indazole-3-carboxamide [**123**];

N-isopropyl-5-(5-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide [**124**];

N-isopropyl-5-(5-(piperidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide [**125**];

N-isopropyl-5-(5-morpholinopyridin-3-yl)-1H-indazole-3-carboxamide [**126**];

5-(5-((dimethylamino)methyl)pyridin-3-yl)-N-isopropyl-1H-indazole-3-carboxamide [**127**];

5-(5-(3,3-dimethylureido)pyridin-3-yl)-N-isopropyl-1H-indazole-3-carboxamide [**137**];

5-(5-(cyclopropanecarboxamido)pyridin-3-yl)-N-isopropyl-1H-indazole-3-carboxamide [**138**];

5-(5-((dimethylamino)methyl)pyridin-3-yl)-N-(pentan-3-yl)-1H-indazole-3-carboxamide [**1159**];

N-((1-methylpiperidin-4-yl)methyl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide [**1187**];

N-(tert-butyl)-5-(5-((dimethylamino)methyl)pyridin-3-yl)-1H-indazole-3-carboxamide [**1198**];

5-(5-((dimethylamino)methyl)pyridin-3-yl)-N-(pentan-3-yl)-1H-indazole-3-carboxamide [**1199**];

N-(tert-butyl)-5-(5-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide [**1214**];

N-(pentan-3-yl)-5-(5-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide [**1215**];

N-isopropyl-5-(5-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide [**1245**];

5-(5-((diethylamino)methyl)pyridin-3-yl)-N-isopropyl-1H-indazole-3-carboxamide [**1246**]; or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

14. Use of a compound according to claims 1-12, or a pharmaceutically acceptable salt thereof, in the preparation of a pharmaceutical composition for treating a disorder or disease in a patient, wherein the disorder or disease is selected from the group consisting of: cancer, pulmonary fibrosis, a bone or cartilage disease, a neurological disorder, osteoarthritis, lung disease, a fibrotic disorder.

15. Use of a compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, in the preparation of a pharmaceutical composition for treating a disorder or disease in a patient, wherein the disorder or disease is selected from the group consisting of: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.

16. The use according to claim 14, wherein the disorder or disease is cancer.

17. The use according to claim 14, wherein the disorder or disease is pulmonary fibrosis.

18. The use according to claim 14, wherein the disorder or disease is a bone or cartilage disease.

19. The use according to claim 14, wherein the disorder or disease is a neurological disorder, wherein the neurological condition/disorder/disease is selected from the group consisting of: frontotemporal dementias, dementia with lewy bodies, prion diseases, Parkinson's disease, Huntington's disease, progressive supranuclear palsy,

corticobasal degeneration, multiple system atrophy, amyotrophic lateral sclerosis (ALS), inclusion body myositis, autism, degenerative myopathies, a metabolic neuropathy, endocrine neuropathies, orthostatic hypotension, multiple sclerosis and Charcot-Marie-Tooth disease.

20. The use according to claim 14, wherein the disorder or disease is a neurological disorder associated with tau protein, amyloid, or alpha-synuclein pathology.

21. The use according to claim 20, wherein the disorder or disease is selected from the group consisting of: Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism-17 (FTDP-17), Lewy body dementia, Parkinson's Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Huntington's Disease, Multiple Sclerosis; Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor, and Stroke.

22. The use according to claim 14, wherein the disorder or disease is osteoarthritis.

23. The use according to claim 14, wherein the disorder or disease is lung disease.

24. The use according to claim 14, wherein the disorder or disease is a fibrotic disorder, wherein the fibrotic disorder is selected from the group consisting of: skin fibrosis; scleroderma; progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; adhesions; chronic obstructive pulmonary disease; fibrosis following myocardial infarction; pulmonary fibrosis; fibrosis and scarring associated with diffuse/interstitial lung disease; central nervous system fibrosis; fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis; endometriosis; ischemic disease; and radiation fibrosis.

25. The use according to claim 14, wherein the patient is a human.

26. The use according to claim 16, wherein the cancer is selected from the group consisting of: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, acute lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma, and ovarian cancer.

27. The use according to claim 16, wherein the cancer is selected from the group consisting of: lung cancer - non-small cell, lung cancer - small cell, multiple myeloma,

nasopharyngeal cancer, neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma,
salivary gland cancer, skin cancer - basal and squamous cell, skin cancer – melanoma, small intestine cancer, stomach cancers, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestational trophoblastic disease, gastrointestinal stromal tumor, gastrointestinal carcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus cancer, endometrial cancer, colorectal cancer, cervical cancer, brain or spinal cord tumor, bone metastasis, bone cancer, bladder cancer, bile duct cancer, anal cancer, and adrenal cortical cancer.

28. The use according to claim 14, wherein the compound inhibits one or more proteins in the Wnt pathway.

29. The use according to claim 28, wherein the compound inhibits signaling induced by one or more Wnt proteins.

30. The use according to claim 29, wherein one or more Wnt proteins are chosen from: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.

31. The use according to claim 14, wherein the compound inhibits DYRK1A.

32. The use according to claim 14, wherein the compound inhibits a kinase activity.

33. Use of a compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, in the preparation of a pharmaceutical composition for preventing or reducing angiogenesis in a patient.